Spinal Muscular Atrophy, Muscular dystrophy, Normal tension glaucoma, Primary immunodeficiency disease, Li-Fraumeni syndrome, Shwachman-Diamond syndrome, Drug-induced acute pancreatitis, Lung-disease
Conditions
Interventions
harvest skin sample from patients
Sponsors
National Hospital Organization, Nagara Medical Center
Gifu Pharmaceutical University, Osaka Toneyama Medical Center, Tokyo Medical Center, Kobe University, Kanazawa University, Kyoto University, Gifu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have been confirmed clinically and molecularly biology with refractory disease. Patients who have established disease-specific iPS cells after informed consent at an external research institution.
Exclusion criteria
Exclusion criteria: Patients who are judged inappropriate by the doctor's judgment. Patients infected with human immunodeficiency virus, human hepatitis B virus, and human hepatitis C virus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of the phenotype of differentiated cells derived from patients | — |
Countries
Japan
Contacts
Public ContactMichinori Funato
National Hospital Organization, Nagara Medical Center Department of Clinical Research
Outcome results
None listed